Therapeutics News and Research

RSS

Texas Tech Professor receives NIH grant to research on leishmaniasis

A Texas Tech University biology professor received a five-year, $1.6 million grant from the National Institutes of Health to study the biochemistry of a microscopic parasite responsible for the tropical disease leishmaniasis in the hope of finding a cure.

2 Apr 2013

Revance Therapeutics raises $33M in Series E financing

Revance Therapeutics, Inc., a privately held specialty biopharmaceutical company developing novel botulinum toxin products for use in aesthetic and therapeutic indications, today announced that it has raised $33 million of its Series E growth financing.

2 Apr 2013

NewLink Genetics starts Phase 2 clinical study of indoximod in patients with metastatic breast cancer

NewLink Genetics Corporation, a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the initiation of a double-blind, randomized, placebo-controlled Phase 2 clinical study of its first IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor, indoximod, in patients with metastatic breast cancer.

2 Apr 2013

Ensemble Therapeutics to highlight IL-17A inhibitor Ensemblin at 245th ACS National Meeting

Ensemble Therapeutics today announced that preclinical data showing the advantages of its Ensemblins, novel macrocyclic compounds against challenging drug targets, will be presented at the 245th American Chemical Society National Meeting being held April 7-11, 2013 in New Orleans, LA.

2 Apr 2013

Adenosine Therapeutics to explore strategic options for Stedivaze

Adenosine Therapeutics, LLC, a drug discovery and development company founded in 1999, announced today that it has engaged Needham & Company to explore strategic options for Stedivaze, a highly selective adenosine A2A agonist being developed as a pharmacological stress agent for use in Myocardial Perfusion Imaging.

2 Apr 2013

Study links mutated histone protein to rare brain stem cancer in children

Most cancer treatments are blunt. In an attempt to eradicate tumors, oncologists often turn to radiation or chemotherapy, which can damage healthy tissue along with the cancerous growths.

2 Apr 2013

IGDRASOL to present updates on Cynviloq at AACR annual meeting

Sorrento Therapeutics, Inc. and IGDRASOL announced today that IGDRASOL will be presenting updates of its development of Cynviloq (IG-001) at the annual meeting of the American Association for Cancer Research in Washington, DC (April 6th to 10th).

1 Apr 2013

Johns Hopkins scientists identify role of central nervous system cell in development of ALS

Johns Hopkins scientists say they have evidence from animal studies that a type of central nervous system cell other than motor neurons plays a fundamental role in the development of amyotrophic lateral sclerosis, a fatal degenerative disease.

1 Apr 2013

Cytori receives patent for methods of treating renal diseases using ADRCs

Cytori Therapeutics received US Patent No. 8,404,229 (the '229 patent) for methods of treating renal diseases using adipose-derived regenerative cells (ADRCs).

30 Mar 2013

Exosomes can transfer membrane proteins, study reveals

Important new research from UMass Medical School demonstrates how exosomes shuttle proteins from neurons to muscle cells where they take part in critical signaling mechanisms, an exciting discovery that means these tiny vehicles could one day be loaded with therapeutic agents, such as RNA interference, and directly target disease-carrying cells.

28 Mar 2013

Lightlake to present Phase II clinical trial results of opioid antagonist nasal spray at APA Annual Meeting

Lightlake Therapeutics Inc., an early stage biopharmaceutical company developing addiction treatments, announced today that a scientific abstract based on results of the Company's Phase II clinical trial of its opioid antagonist nasal spray treatment for patients with Binge Eating Disorder has been accepted for presentation at the American Psychiatric Association Annual Meeting taking place in San Francisco, California, May 18-22, 2013.

27 Mar 2013

Research paper highlights implementation of infectious disease curriculum in Boston Public Schools

A research paper published online this month in Academic Medicine highlights the successful development, implementation, and effects of an infectious disease curriculum that has now been piloted in five Boston Public Schools.

27 Mar 2013

Three Ludwig scientists named as Fellows in inaugural class of AACR Academy

Three Ludwig scientists were named as Fellows in the inaugural class of the AACR Academy, the most prestigious honor bestowed by the American Association for Cancer Research.

27 Mar 2013

Study provides important insight into how BMT treatment works in patients with MS

A new study by Multiple Sclerosis researchers at three leading Canadian centres addresses why bone marrow transplantation has positive results in patients with particularly aggressive forms of MS.

27 Mar 2013

Scientists find new mechanism for guiding growth of nerves

A new mechanism for guiding the growth of nerves that involves cell-death machinery has been found by scientists at the University of Nevada, Reno that may bring advances in neurological medicine and research.

26 Mar 2013

UCI study finds novel molecular mechanism that helps trigger formation of long-term memory

UC Irvine neurobiologists have found a novel molecular mechanism that helps trigger the formation of long-term memory. The researchers believe the discovery of this mechanism adds another piece to the puzzle in the ongoing effort to uncover the mysteries of memory and, potentially, certain intellectual disabilities.

26 Mar 2013

arGEN-X advances ARGX-112 into formal preclinical development

arGEN-X, a clinical stage biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announces that it has progressed ARGX-112, its fourth therapeutic candidate, into formal preclinical development.

25 Mar 2013

Scientists identify potential treatment for idiopathic pulmonary fibrosis

Investigators at the University of Alabama at Birmingham (UAB) have unlocked another piece of the puzzle surrounding idiopathic pulmonary fibrosis, an often fatal lung disease with no cure and no effective treatments.

25 Mar 2013

Epizyme receives patent for drug candidate for genetically defined type of non-Hodgkin lymphomas

Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that it has received a Notice of Issuance from the U.S. Patent and Trademark Office for its patent application entitled "ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS", U.S. Patent No.: 8,410,088.

24 Mar 2013

Findings provide structural basis for development of drugs to fight enterovirus 71 infection

New research findings may help scientists design drugs to treat a virus infection that causes potentially fatal brain swelling and paralysis in children.

22 Mar 2013

Therapeutics News and Research

Texas Tech Professor receives NIH grant to research on leishmaniasis

Revance Therapeutics raises $33M in Series E financing

NewLink Genetics starts Phase 2 clinical study of indoximod in patients with metastatic breast cancer

Ensemble Therapeutics to highlight IL-17A inhibitor Ensemblin at 245th ACS National Meeting

Adenosine Therapeutics to explore strategic options for Stedivaze

Study links mutated histone protein to rare brain stem cancer in children

IGDRASOL to present updates on Cynviloq at AACR annual meeting

Johns Hopkins scientists identify role of central nervous system cell in development of ALS

Cytori receives patent for methods of treating renal diseases using ADRCs

Exosomes can transfer membrane proteins, study reveals

Lightlake to present Phase II clinical trial results of opioid antagonist nasal spray at APA Annual Meeting

Research paper highlights implementation of infectious disease curriculum in Boston Public Schools

Three Ludwig scientists named as Fellows in inaugural class of AACR Academy

Study provides important insight into how BMT treatment works in patients with MS

Scientists find new mechanism for guiding growth of nerves

UCI study finds novel molecular mechanism that helps trigger formation of long-term memory

arGEN-X advances ARGX-112 into formal preclinical development

Scientists identify potential treatment for idiopathic pulmonary fibrosis

Epizyme receives patent for drug candidate for genetically defined type of non-Hodgkin lymphomas

Findings provide structural basis for development of drugs to fight enterovirus 71 infection

Advancing therapeutic biopolymer development eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News